Table V.

Multivariate cox-regression analyses of prognosis factors with DFS and OS.

	DFS			OS
Prognosis factors	HR	95% CI	P-valuea	HR	95% CI	P-valuea
Number of lymph nodes involved
0	1.00			1.00
1–3	0.96	0.28–3.27	0.949	1.75	0.54–5.71	0.353
≥4	5.79	1.73–19.32	0.004	12.90	3.57–46.59	0.000
Chemotherapy
No chemotherapy	1.00			1.00
Derivative regimens of CAF	6.00	1.26–28.46	0.024	1.36	0.31–5.92	0.681
(CAF, CEF, CTF or IEF)
Regimens including taxanes	11.11	2.61–47.39	0.001	1.84	0.54–6.20	0.328
(TE, TC or TAC)
Other regimens	2.18	0.46–10.44	0.329	0.28	0.05–1.64	0.158
Vimentin
Negative	1.00			1.00
Positive	4.15	1.53–11.28	0.005	2.88	0.96–8.61	0.059
Basal-like
EGFR and CK5/6 negative	1.00			1.00
EGFR or CK5/6 positive	1.96	0.78–4.93	0.151	3.17	1.28–7.82	0.013
Aldehyde dehydrogenase 1
Grade 0	1.00			1.00
Grade 1+	0.61	0.14–2.58	0.605	0.57	0.11–2.87	0.492
Grade 2+	0.33	0.09–1.23	0.329	0.44	0.10–1.94	0.279
Grade 3+	1.30	0.42–4.06	1.298	1.40	0.44–4.43	0.571
CD44/CD24 status
CD44−/CD24−	1.00			1.00
CD44+/CD24−	2.38	0.90–6.33	0.081	4.38	1.57–12.18	0.005
CD44+/CD24+	0.38	0.03–4.44	0.438	0.89	0.09–8.99	0.920
CD44−/CD24+	0.59	0.18–1.98	0.393	1.24	0.38–4.01	0.722

DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; CD, cluster of differentiation; CK5/6, cytokeratin 5/6; CAF, cyclophosphamide, adriamycin and fluorouracil; CEF, cyclophosphamide, epirubicin and fluorouracil; CTF, cyclophosphamide, pirarubicin and fluorouracil; IEF, ifosfamide, epirubicin and fluorouracil; TE, paclitaxel or docetaxel and epirubicin; TC, docetaxel and cyclophosphamide; TAC, docetaxel, adriamycin and cyclophosphamide.

^aP<0.05 was considered to indicate a statistically significant difference.